Immunome (IMNM) vs Disc Medicine (IRON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immunome (IMNM) has outperformed Disc Medicine (IRON) over the past year, gaining 36.8% versus a loss of 12.3%. Over five years, IMNM leads with a +11.0% price change compared with -44.4% for IRON. Disc Medicine is the larger company by market cap ($2.38 billion vs $2.31 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNM | IRON |
|---|---|---|
| Share price | $19.55 | $62.06 |
| Market cap | $2.31B | $2.38B |
| 1-day change | +1.24% | +2.12% |
| YTD return | -8.99% | -21.85% |
| 1-year return | +36.81% | -12.28% |
| 5-year return | +11.02% | -44.39% |
| EPS (TTM) | $-2.55 | $-6.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.94M | — |
| Revenue growth (YoY) | -23.23% | — |
| Net income (latest FY) | $-212.39M | $-212.18M |
| Operating margin | -3228.83% | — |
| Net margin | -3059.99% | — |
| 52-week high | $30.06 | $99.50 |
| 52-week low | $13.49 | $40.00 |
| Distance from 52-week high | -34.96% | -37.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +80.05% | +66.24% |
| Average volume | 1.20M | 471.18K |
| Shares outstanding | 118.00M | 38.39M |
| Employees | 247 | 165 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMNM has outperformed IRON by 49.1 percentage points over the past year.
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 247 employees
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 165 employees
IMNM vs IRON FAQ
Which is bigger, Immunome or Disc Medicine?
Disc Medicine (IRON) is larger, with a market capitalization of $2.38B compared with $2.31B for Immunome (IMNM).
Which stock has performed better over the past year, IMNM or IRON?
IMNM returned +36.81% over the past 12 months, compared with -12.28% for IRON (price return, excluding dividends). Past performance does not predict future results.
Are Immunome and Disc Medicine in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.